NO960393D0 - Heterosykliske fenylforbindelser som COX-2-inhibitorer - Google Patents

Heterosykliske fenylforbindelser som COX-2-inhibitorer

Info

Publication number
NO960393D0
NO960393D0 NO960393A NO960393A NO960393D0 NO 960393 D0 NO960393 D0 NO 960393D0 NO 960393 A NO960393 A NO 960393A NO 960393 A NO960393 A NO 960393A NO 960393 D0 NO960393 D0 NO 960393D0
Authority
NO
Norway
Prior art keywords
cox
inhibitors
phenyl compounds
heterocyclic phenyl
heterocyclic
Prior art date
Application number
NO960393A
Other languages
English (en)
Other versions
NO960393L (no
Inventor
Yves Ducharme
Jacques Yves Gauthier
Petpiboon Prasit
Yves Leblanc
Zhaoyin Wang
Serge Leger
Michel Therien
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/179,467 external-priority patent/US5474995A/en
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of NO960393D0 publication Critical patent/NO960393D0/no
Publication of NO960393L publication Critical patent/NO960393L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/24Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58One oxygen atom, e.g. butenolide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
NO960393A 1994-01-10 1996-01-30 Heterosykliske fenylforbindelser som COX-2-inhibitorer NO960393L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/179,467 US5474995A (en) 1993-06-24 1994-01-10 Phenyl heterocycles as cox-2 inhibitors
PCT/CA1994/000688 WO1995018799A1 (en) 1994-01-10 1994-12-19 Phenyl heterocycles as cox-2 inhibitors

Publications (2)

Publication Number Publication Date
NO960393D0 true NO960393D0 (no) 1996-01-30
NO960393L NO960393L (no) 1996-07-09

Family

ID=22656713

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960393A NO960393L (no) 1994-01-10 1996-01-30 Heterosykliske fenylforbindelser som COX-2-inhibitorer

Country Status (12)

Country Link
EP (1) EP0739340A1 (no)
JP (1) JP2788677B2 (no)
CN (1) CN1143365A (no)
AU (1) AU1269495A (no)
BG (1) BG63082B1 (no)
BR (1) BR9408478A (no)
CA (1) CA2180651A1 (no)
FI (1) FI108792B (no)
HU (1) HUT74986A (no)
NO (1) NO960393L (no)
SG (1) SG43841A1 (no)
WO (1) WO1995018799A1 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715676B2 (en) * 1993-03-12 2000-02-10 Merck Frosst Canada & Co. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
MX9800568A (es) * 1995-07-19 1998-04-30 Merck & Co Inc Uso de agentes anti-inflamatorios no esteroidales.
KR100373622B1 (ko) * 1996-05-17 2003-07-12 머크 앤드 캄파니 인코포레이티드 사이클로옥시게나제-2로매개된질환의1일1회치료용조성물
AU775030B2 (en) * 1996-05-17 2004-07-15 Merck Frosst Company Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
ATE271547T1 (de) * 1997-03-14 2004-08-15 Merck Frosst Canada Inc Pyridazinone als inhibitoren von cyclooxygenase-2
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
WO1998046594A1 (en) * 1997-04-11 1998-10-22 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and cox inhibitors containing them
WO1998051667A1 (en) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Indole derivatives and mono- and diazaindole derivatives
ATE281458T1 (de) 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
JP2003523330A (ja) 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
US6465509B2 (en) 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
AU2003247622A1 (en) 2002-06-27 2004-01-19 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2004315596B2 (en) 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
KR20050051729A (ko) * 2003-11-28 2005-06-02 일양약품주식회사 사이클로 옥시게나제-2 억제제인 페닐 헤테로사이클의제조방법
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
CA2610694A1 (en) 2005-05-31 2006-12-07 Mylan Laboratories, Inc. Compositions comrising nebivolol
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
AU2007227613A1 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2891885A3 (en) 2007-04-18 2015-10-14 Health Diagnostic Laboratory, Inc. Diabetes-related biomarkers and methods of use thereof
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
KR20120139723A (ko) 2010-02-01 2012-12-27 더 호스피탈 포 식 칠드런 재발협착증의 치료 및 예방을 위한 원격 허혈 처치
CN102939054A (zh) 2010-03-31 2013-02-20 儿童医院 远端缺血处理改进心肌梗死之后的结果的用途
NZ728724A (en) 2012-05-11 2018-03-23 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2012716A1 (en) * 1989-03-22 1990-09-22 Akito Tanaka Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
AU7559691A (en) * 1990-04-17 1991-11-11 Allergan, Inc. 2(5h)-furanones substituted in the 5 and or in the 4 position, as anti-inflammatory agents
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
CA2152792C (en) * 1993-01-15 2000-02-15 Stephen R. Bertenshaw Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
JPH09501920A (ja) * 1993-08-19 1997-02-25 ワーナー−ランバート・コンパニー 非ペプチドエンドセリンアンタゴニスト▲i▼

Also Published As

Publication number Publication date
BG63082B1 (bg) 2001-03-30
EP0739340A1 (en) 1996-10-30
CN1143365A (zh) 1997-02-19
FI962800L (fi) 1996-09-06
AU1269495A (en) 1995-08-01
SG43841A1 (en) 1997-11-14
HUT74986A (en) 1997-03-28
BG100350A (bg) 1996-12-31
FI962800A0 (fi) 1996-07-09
NO960393L (no) 1996-07-09
WO1995018799A1 (en) 1995-07-13
JP2788677B2 (ja) 1998-08-20
HU9601875D0 (en) 1996-09-30
BR9408478A (pt) 1997-08-26
CA2180651A1 (en) 1995-07-13
FI108792B (fi) 2002-03-28
JPH09506631A (ja) 1997-06-30

Similar Documents

Publication Publication Date Title
NO960393D0 (no) Heterosykliske fenylforbindelser som COX-2-inhibitorer
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
FI965126A7 (fi) Tri-substituoidut PDE IV -inhibiittoreina hyödylliset fenyylijohdannaiset
IS5338A (is) Ný spíróasabísýklísk heterósýklísk efnasambönd
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK0925287T3 (da) Heterocykliske metalloproteaseinhibitorer
DK0923561T3 (da) Heterocykliske metalloproteaseinhibitorer
FI962749L (fi) Uusia heterosyklisiä yhdisteitä
DK1100797T3 (da) Heterocycliske forbindelser som inhibitorer af rotamaseenzymer
EE9900259A (et) Ühendi uus vorm
FI971104A0 (fi) Menetelmä COX-inhibiittoreina käyttökelpoisten fenyyliheterosyklien valmistamiseksi
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
NO992725D0 (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
PT907650E (pt) N-¬4-(heteroarilmetil)fenil|heteroarilaminasc
DK1060178T3 (da) Heterocyklisk forbindelser som inhibitorer af rotamase enzymer
FI990922A0 (fi) Uusia yhdisteitä
DK0820451T3 (da) Hidtil ukendte heterocykliske forbindelser
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
NO993161D0 (no) Cyklooksygenaseinhibitor
NO995430D0 (no) Nye heterosykliske forbindelser
FI963509A0 (fi) Isoksatsoliiniyhdisteitä 5-lipoksigenaasi-inhibiittoreina
FI941265A7 (fi) Heterosyklisiä sulfoniamidotrombiini-inhibiittoreita
ID18481A (id) 2-(3,5-difluorofenil)-3-(4-metilsulfonil)fenil)-2-siklopenten-1-on yang berguna sebagai inhibitor cox-2
SE9400968D0 (sv) Heterocyclic compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application